Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity

NCT ID: NCT06425042

Last Updated: 2025-07-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-01
• Study Completion Date: 2026-03-31

Brief Summary

The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.

Conditions

Healthy Aging; Lifestyle-related Condition; Metabolic Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

NR+EXTR

This arm will ingest NR orally and perform exercise training

Group Type: EXPERIMENTAL

Nicotinamide Riboside (NR)

Intervention Type: DIETARY_SUPPLEMENT

Participants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program

PLA+EXTR

This arm will ingest placebo orally and perform exercise training

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Participants will ingest 1g/d of placebo orally during 12 weeks in parallel to a exercise training program

Interventions

Nicotinamide Riboside (NR)

Participants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Participants will ingest 1g/d of placebo orally during 12 weeks in parallel to a exercise training program

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Participants are able to provide signed and dated written informed consent prior to any study specific procedures
• Aged ≥ 60 and ≤ 80 years
• Body mass index (BMI) 25 - 35 kg/m2
• Stable dietary habits (no weight loss or gain > 5 kg in the past 3 months)
• No signs of active cardiovascular disease, liver or kidney malfunction

Exclusion Criteria

• Patients with congestive heart failure and and/or severe renal and or liver insufficiency
• Uncontrolled hypertension
• Any contra-indication for MRI scanning
• Alcohol consumption of > 3 servings per day for man and >2 servings per day for woman
• Smoking
• Unstable body weight (weight gain or loss > 5kg in the last 3 months)
• Engagement in structured exercise activities > 2 hours a week
• Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator which would possibly hamper our study results
• Use of food supplements containing NR or Resveratrol (similar working mechanisms)

• Minimum Eligible Age: 60 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Finis Terrae University

OTHER

Sponsor Role: lead

Responsible Party

Rodrigo Mancilla

Doctor, PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Finis Terrae University

Santiago, Santiago Metropolitan, Chile

Site Status: RECRUITING

Countries

Chile

Central Contacts

Rodrigo Mancilla, PhD

Role: CONTACT

rmancilla@uft.cl

+56953676588

Facility Contacts

Rodrigo Mancilla, PhD

Role: primary

Other Identifiers

23-041

Identifier Type: -

Identifier Source: org_study_id